BridgeBio Pharma, Inc.
MUN:2CL Voorraadrapport
Marktkapitalisatie: €4.6b
BridgeBio Pharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6 De winst van BridgeBio Pharma is gedaald met een gemiddeld jaarlijks percentage van -14%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 7.7%. De inkomsten zijn groeide met een gemiddeld percentage van 36% per jaar.
Belangrijke informatie
-4.0%
Groei van de winst per aandeel
Biotechs Groei van de industrie -14.6% Inkomstengroei 36.0% Rendement op eigen vermogen n/a Nettomarge -207.1% Laatste winstupdate 30 Jun 2024
Recente prestatie-updates uit het verleden
Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023) Aug 02
Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022) Feb 23
Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022) Aug 04
Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021) Feb 24
Toon alle updates
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Oct 01
BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024 Aug 31
BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney Aug 19
Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023) Aug 02 BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Jul 23
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Jun 19
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia Jun 05
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population May 14
BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024 Apr 28
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Apr 09 BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 07
BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 06
BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering. Mar 05
Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022) Feb 23
New major risk - Financial position Feb 22
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy Feb 06
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months Feb 03
BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine Jan 11
BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia Dec 14
BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Nov 14
BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9 Oct 10
BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors Sep 27 BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors Sep 26
Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia Sep 07
BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023 Aug 28
New minor risk - Financial position Aug 06
Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022) Aug 04
Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study Aug 01
Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy Jul 18
BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia Jun 21
Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021) Feb 24
Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 Dec 24
BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Oct 15
BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society Oct 14
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib) Oct 12
BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium Oct 08
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Sep 21
BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671 Aug 19
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Aug 11
BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2 Jul 28
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A Jul 27
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers Jun 28
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease Jun 23
BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Jun 14
BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations Jun 11
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias May 28 BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01 May 21
BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022 May 02
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Apr 04
Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO). Mar 10
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) Jan 28
Independent Director recently bought €264k worth of stock Jan 01
Hoe BridgeBio Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis MUN:2CL Opbrengsten, kosten en inkomsten (USD Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Jun 24 219 -454 209 511 31 Mar 24 219 -538 185 504 31 Dec 23 9 -643 151 456 30 Sep 23 9 -613 135 416 30 Jun 23 6 -573 130 384 31 Mar 23 78 -425 131 385 31 Dec 22 78 -481 143 399 30 Sep 22 89 -491 166 431 30 Jun 22 91 -509 181 443 31 Mar 22 71 -596 191 436 31 Dec 21 70 -563 189 451 30 Sep 21 57 -535 172 419 30 Jun 21 63 -495 162 407 31 Mar 21 9 -520 154 391 31 Dec 20 8 -449 146 337 30 Sep 20 22 -402 143 304 30 Jun 20 41 -346 131 268 31 Mar 20 41 -291 110 233 31 Dec 19 41 -261 94 210 30 Sep 19 27 -226 74 204 30 Jun 19 0 -197 61 180 31 Mar 19 0 -155 54 151 31 Dec 18 0 -131 44 140
Kwaliteitswinsten: 2CL is momenteel verliesgevend.
Groeiende winstmarge: 2CL is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2CL is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 14% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van 2CL over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: 2CL is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( -21.2% ).
Rendement op eigen vermogen
Hoge ROE: De schulden van 2CL zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}